Sichuan Kelun Pharmaceutical (002422.SZ): Imipenem cilastatin sodium/sodium chloride injection for injection granted registration approval.

Sichuan Kelun Pharmaceutical (002422.SZ) announces that its subsidiary, Hunan Kelun Pharmaceutical Co., Ltd., has recently obtained drug registration approval from the National Medical Products Administration for the chemical drug "Imipenem/cilastatin sodium/chloride injection". Imipenem is the world's first carbapenem antibiotic to be marketed. When combined with cilastatin sodium, it can avoid renal metabolism deactivation and improve kidney safety. It has the characteristics of stable beta-lactamase, broad antibacterial spectrum, and strong antibacterial activity, especially suitable for a variety of pathogen infections, aerobic and anaerobic bacterial mixed infections, and early treatment before the pathogen is identified.